Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has become a global epidemic and poses a major …

Abstract Coronavirus disease 2019 (COVID-19) pneumonia outbreak started in December
2019. On March 12, 2020, the World Health Organization (WHO) declared that the severe …

Background Studies on a new coronavirus disease (COVID-19) show the elevation of liver
enzymes and liver fibrosis index (FIB-4) independently on pre-existing liver diseases. It …

Liver involvement in Coronavirus Disease 2019 (COVID-19) has been widely documented.
However, data regarding liver-related prognosis are scarce and heterogeneous. The current …

Background and Aim. The relationship between liver fibrosis scores and clinical outcomes in
patients with COVID‐19 is not compressively assessed. Methods. We identified relevant …

Methods We performed a comprehensive literature search of PubMed, Embase, and Scopus
databases on 26 November 2020. FIB-4 was calculated by [age (years)× AST (IU/L)]/[platelet …

Background and Aims We investigated the association between liver fibrosis scores and
clinical outcomes in patients with COVID-19. Methods We performed a post-hoc analysis …

Abstract Coronavirus disease 2019 (COVID-19) has affected patients with pre-existing
chronic liver disease (CLD) in various ways. The maximum impact was seen on patients with …

Objective: to screen putative associations between liver markers and proinflammatory-
related features concerning infectious morbidity and fatal outcomes in COVID-19 patients …

Background & aims SARS-Cov-2 infection manifests as a wide spectrum of clinical
presentation and even now, despite the global spread of the vaccine, contagiousness is still …